Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]

Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs

Status: Suspended
Expected date of issue: TBC
Referral date: April 2010
Process: STA

Scoped within batch 10

Topic area:

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Whitney Miller
Communications manager: Tonya Gillis
Project manager: Jeremy Powell


Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC


Consultees and commentators



Commentators (no right to submit or appeal)



  • Rituximab (Roche Products)

Patient/carer groups

  • Action on Pain
  • Afiya Trust
  • Arthritic Association
  • Arthritis & Musculoskeletal Alliance (ARMA)
  • Arthritis Care
  • Black Health Agency
  • Chinese National Healthy Living Centre
  • Counsel and Care
  • Equalities National Council
  • Leonard Cheshire Disability
  • Muslim Council of Britain
  • Muslim Health NetworkNational Rheumatoid Arthritis Society
  • Pain Concern
  • Pain Relief Foundation
  • Royal Association for Disability & Rehabilitation (RADAR)
  • South Asian Health Foundation
  • Specialised Healthcare Alliance

Professional groups

  • British Association for Services to the Elderly
  • British Geriatrics Society
  • British Health Professionals in Rheumatology
  • British Institute of Musculoskeletal Medicine
  • British Institute of Radiology
  • British Orthopaedic Association
  • British Pain Society
  • British Society for Rheumatology
  • British Society of Rehabilitation Medicine
  • Physiotherapy Pain Association
  • Primary Care Rheumatology Society
  • Rheumatoid Arthritis Surgical Society
  • Royal College of Anaesthetists
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
  • Royal College of Radiologists
  • Royal College of Surgeons
  • Royal Pharmaceutical Society
  • Royal Society of Medicine รข?? Intellectual Disabilities Forum
  • Society and College of Radiographers
  • United Kingdom Clinical Pharmacy Association


  • Bradford and Airedale Teaching PCT
  • Department of Health
  • NHS Hertfordshire
  • Welsh Assembly Government


  • Board of Community Health Councils in Wales
  • British National Formulary
  • Care Quality Commission
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency
  • National Association of Primary Care
  • NHS Alliance
  • NHS Commercial Medicines Unit
  • NHS Confederation
  • NHS Quality Improvement Scotland
  • Public Health Wales NHS Trust
  • Scottish Medicines Consortium

Comparator manufacturer(s)

  • AAH Pharmaceuticals (azathioprine, sulfasalazine, penicillamine)
  • Abbott Laboratories (adalimumab)
  • Actavis (azathioprine, sulfasalazine, penicillamine)
  • Almus Pharmaceuticals (sulfasalazine)
  • Arrow Generics (azathioprine)
  • AstraZeneca (chloroquine)
  • Focus Pharmaceuticals (azathioprine)
  • Genesis Pharmaceuticals (sulfasalazine)
  • GlaxoSmithKline (azathioprine)
  • Kent Pharmaceuticals (azathioprine, sulfasalazine, penicillamine)
  • Metwest Pharmaceuticals (sulfasalazine)
  • Mylan (azathioprine, sulfasalazine, penicillamine)
  • Novartis (ciclosporin)
  • Pfizer (sulfasalazine)
  • Rosemont Pharmaceuticals (sulfasalazine)
  • Sandoz (azathioprine)
  • Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate)
  • Schering-Plough (infliximab, golimumab)
  • Teva UK (azathioprine, sulfasalazine, penicillamine)
  • Tillomed Laboratories (azathioprine)
  • UCB Pharma (certolizumab pegol)
  • Wyeth Pharmaceuticals (etanercept)

Relevant research groups

  • Arthritis Research Campaign
  • Chronic Pain Policy Coalition
  • MRC Clinical Trials Unit
  • National Institute for Health Research
  • Policy Research Institute on Ageing and Ethnicity
  • Research Institute for the Care of Older People

Evidence Review Group

  • West Midlands Health Technology Assessment Collaboration
  • National Institute for Health Research Health Technology Assessment Programme
  • Associated Guideline Groups
  • National Clinical Guideline Centre
  • Associated Public Health Groups
  • None



Project history

Date Update
22 March 2011

The manufacturer has informed us that they will not be seeking a license for this particular indication at the present time.

NICE has therefore decided to suspend this appraisal from its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.”



Key documents

This page was last updated: 05 July 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.